Sanofi Board Forces Out CEO Chris Viehbacher Amid Lantus Woes
This article was originally published in The Tan Sheet
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
You may also be interested in...
A six-part contingent value right included along with Sanofi-Aventis’ cash payment of $74 a share (about $20.1 billion) for Genzyme should enable both companies’ shareholders to share in the potential upside of Lemtrada (alemtuzumab) if it is approved as a treatment for multiple sclerosis.
French drug maker Sanofi-Aventis is establishing an OTC division and plans to double revenues from nonprescription drug products within five years
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.